Patterns of HIV and SARS-CoV-2 co-infection in Wuhan, China

Wei Guo1,2*, Fangzhao Ming3*, Yong Feng4*, Qian Zhang5, Pingzhen Mo6, Lian Liu7, Ming Gao8, Weiming Tang9,10 and Ke Liang6,§,†

*Corresponding author: Ke Liang, Department of Infectious Diseases Zhongnan Hospital in Wuhan University, Wuhan, 430071, China. Tel: +86-15327198964. (keliang@whu.edu.cn)
§These authors equally contributed to this manuscript and are co-first authors.
†These authors contributed equally.

Keywords: clinical patterns; HIV; SARS-CoV-2; Co-infection; COVID-19; CD4+ T lymphocyte count; lymphopenia

Received 6 May 2020; Accepted 12 June 2020

People living with HIV/AIDS (PLWHA) were initially considered to be at an increased risk of infection with SARS-CoV-2 due to their risk of immunosuppression [1]. However, few studies have reported on co-infections between HIV and SARS-CoV-2 and treatment outcomes, and data to date do not support either increased acquisition or severity of COVID-19 [2,3]. Here we present the clinical and laboratory patterns in 14 co-infected cases, including three asymptomatic SARS-CoV-2 carriers in Wuhan, China, from 16 February to 30 April 2020.

The 14 cases were coded P1 to P14 in order of their infection severity, namely: critical (P1 and P2), severe (P3 to P5), mild (P6 to P11) and asymptomatic (P12 to P14) (Table 1). The case group consisted of 13 men who have sex with men (MSM) and one heterosexual female. Only P10 and P13 had smoking history, and none of them abused alcohol.

Ten patients and two asymptomatic carriers showed undetectable HIV viral load (HIV-VL) and CD4+ T lymphocyte count (CD4 count) between 141 to 817/µL prior to SARS-CoV-2 co-infection. Two HIV-VL unsuppressed individuals included patient (P5) who presented with a CD4 count of 34/µL without having ever received antiretroviral therapy (ART), and an asymptomatic carrier (P12) who presented with a CD4 count of 29/µL after two weeks of ART. Four co-morbidity cases presented with a CD4 count less than 200/µL, including two severe cases and two mild cases (All recovered at the end of the study). Although P12 presented with a low CD4 count, he did not even show any symptoms of COVID-19 or any abnormality in the radiograph. This may indicate that low CD4 count did not inevitably lead to death under HIV and SARS-CoV-2 co-infection. On the contrary, the two deaths occurred in cases who had a relatively high CD4 count (350/µL and 695/µL). This finding is consistent with a previous study, which reported one AIDS/COVID-19 patient who presented a low CD4 count (13/µL) and recovered finally [2]. Considering that SARS-CoV-2 might cause multi-organ injury through the inflammatory cytokine storm [4], we hypothesized that previous low CD4 count might act a protective role in preventing hyperimmune response. However, our sample size limits the deduction for a generalized conclusion, and hence large-scale investigation is needed to validate this hypothesis.

The proportion of severe cases (5/11, 45.5%) was higher among the case series than reported in the general population [5]. The COVID-19 mortality rate (18.2%) was also higher than the overall COVID-19 mortality (7.7%, 3869/50333) in Wuhan [6]. The median age among the co-infected cases was older than that of overall patients, and the higher proportion of comorbidities in our patients (8/11, 72.7%) coupled with the senior age might have contributed partially to the higher proportion of severe case and mortality. Living with HIV/AIDS also played a role in leading to comorbidities prior to admission, such as lymphoma and opportunistic infection (pneumocystis pneumonia, PCP).

Reports from laboratory examinations at admission showed leukopenia in six cases and lymphopenia in discrepant six cases. Although the exact immune-pathogenesis of the decrease in lymphocytes in peripheral blood remains unclear, lymphopenia is also reported as a frequent presentation in HIV negative COVID-19 patients, especially in severe cases [5,7]. The pattern of immune cells in AIDS/COVID-19 patients showed minor differences from that of overall COVID-19 patients [8]. However, patients’ CD4 count, HIV-VL and inflammatory cytokines were not tested on the admission, which prevented us from knowing more about the immune status at the early stage of SARS-CoV-2 infection in PLHWA. Another limitation should be mentioned that only one ART naïve COVID-19 case was enrolled in our investigation, although knowing the COVID-19 prognosis in ART naïve patients is critical. However, together with the case series
### Table 1. Clinical features of the COVID-19 patients living with HIV in Wuhan, China, 2020 (N = 14)

| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 | Patient 13 | Patient 14 |
|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| **Demographic and baseline features of the patients** | | | | | | | | | | | | | | |
| Ages (years) | 56 | 68 | 60 | 58 | 38 | 31 | 71 | 63 | 44 | 51 | 44 | 24 | 57 | 64 |
| Sex | Male | Male | Male | Male | Female | Male | Male | Male | Male | Male | Male | Male | Male | Male |
| HIV-risk factor | MSM | MSM | MSM | MSM | Heterosexual | MSM | MSM | MSM | MSM | MSM | MSM | MSM | MSM |
| Comorbidities | COPD | Hypertension | Diabetes | Lymphoma | Hypertension | Atrial fibrillation | PCP | None | Hypertension | None | Hypertension | None | Kaposi's Sarcoma | Pulmonary tuberculosis | Anemia | |
| ART regimen | AZT + 3TC + EFV | AZT + 3TC + NVP | TDF + EFV | RPV + TDF | None | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | Lp/v + 3TC | EVG + FTC + TAF | AZT + 3TC + EFV | TDF + 3TC + EFV | |
| Latest CD4 count (cells/µL) | 695 | 350 | 141 | 722 | 34 | 420 | 586 | 34 | 420 | 586 | 34 | 420 | 586 | 34 |
| Latest HIV-VL (copies/mL) | <20 | <20 | <20 | <20 | <20 | <20 | <20 | <20 | <20 | <20 | <20 | <20 | <20 | <20 |
| **Clinical features on admission** | | | | | | | | | | | | | | |
| Diagnosis symptoms | | | | | | | | | | | | | | |
| Fever | ++ | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Cough | + (dry) | + (dry) | + (dry) | + (dry) | + (dry) | + (dry) | + (dry) | + (dry) | + (dry) | + (dry) | + (dry) | + (dry) | + (dry) | + (dry) |
| Dyspnea | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Blood pressure (mmHg) | 98/45 | 133/90 | 117/69 | 139/79 | 145/93 | 139/79 | 139/79 | 139/79 | 139/79 | 139/79 | 139/79 | 139/79 | 139/79 | 139/79 |
| Body temperature (°C) | 38.6 | 38.5 | 38.3 | 38.1 | 38.5 | 38.4 | 38.7 | 38.7 | 38.7 | 38.7 | 38.7 | 38.7 | 38.7 | 38.7 |
| Oximetry saturation | 76% | 82% | 92% | 87% | 91% | 94% | 96% | 97% | 96% | 98% | 99% | 98% | 98% | 100% |
| Chest CT scan | GGO | Bilateral | GGO | Bilateral | GGO | Bilateral | GGO | Bilateral | GGO | Bilateral | GGO | Bilateral | GGO | Bilateral |
| WBC (×10⁹ cells/L) | 4.36 | 6.7 | 3.41 | 2.29 | 4.2 | 1.83 | 4.51 | 1.65 | 3.1 | 4.44 | 5.2 | 4.32 | 2.16 | 7.04 |
| (normal range: 3.5 to 9.5) | | | | | | | | | | | | | | |
| LYM (×10⁹ cells/L) | 1.1 | 0.35 | 0.9 | 0.62 | 1.55 | 0.95 | 1.45 | 0.41 | 1.6 | 1.86 | 0.68 | 1.22 | 1.13 | 1.44 |
| (normal range: 1.1 to 2.0) | | | | | | | | | | | | | | |
| PLT (×10⁹ cells/L) | 360 | 65 | 95 | 132 | 267 | 120 | 168 | 118 | 234 | 163 | 232 | 383 | 111 | 210 |
| (normal range: 125 to 350) | | | | | | | | | | | | | | |
| IL-6 (pg/mL) | – | 18.62 | – | – | 9.87 | 1408 | – | – | – | 10.21 | – | – | 3.25 | – |
| (normal range: 0 to 7) | | | | | | | | | | | | | | |
| Clinical classification | Critical | Critical | Severe | Severe | Mild | Mild | Mild | Mild | Mild | Mild | Mild | Mild | Asymptomatic carrier | Asymptomatic carrier | Asymptomatic carrier |
| Treatment and clinical outcomes | | | | | | | | | | | | | | |
| Admitted to ICU | None | None | None | None | None | None | None | None | None | None | None | None | None | None |
| Mechanical ventilation | None | None | None | None | None | None | None | None | None | None | None | None | None | None |
| Anti-virus Therapy | None | None | None | None | None | None | None | None | None | None | None | None | None | None |
| ART therapy | AZT + 3TC+ 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP | AZT + 3TC + NVP |
| Antibiotic Therapy | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Corticosteroids | None | None | None | None | None | None | None | None | None | None | None | None | None | None |
| Prognosis | Death | Death | Death | Death | Death | Death | Death | Death | Death | Death | Death | Death | Death | Death |
| Length of hospital stay (days) | 1 | 6 | 18 | 21 | 47 | 11 | 8 | 9 | 24 | 14 | 23 | 10 | 14 | 7 |
| Duration of positive nucleic acid test (days) | – | – | 12 | 17 | 10 | 6 | 6 | 8 | 21 | 10 | 15 | 7 | 4 | 5 |

3TC, Lamivudine; ART, antiretroviral treatment; AZT, Zidovudine; COPD, chronic obstructive pulmonary disease; EFV, Efavirenz; EVG/c, Efavirenz/cidofovir; FTC, Emtricitabine; GGO, ground glass opacity; HIV-VL, HIV viral load; ICU, intensive care unit; LPV/r, Lopinavir/Ritonavir; LYM, lymphocytes; MSM, men who have sex with men; NVP, Nevirapine; PCP, Pneumocystis pneumonia; PLT, platelet; RPV, Ritonavir; TDF, Tenofovir; WBC, white blood cells.

The two patients died. Asymptomatic carrier.
published earlier [3], the previous immune status and the clinical course of all the patients in this study still help to sum up some experiences in treating COVID-19 in PLWHA.

The COVID-19 pandemic has had a significant impact on people around the world, including PLWHA, and continues to grow. Health facilities should endeavour to maintain undisputed antiretroviral supply to PLWHA during the pandemic phase to ensure retention in care and treatment success. Co-infected patients who presented with low CD4 count and high HIV-VL, as well as opportunistic infections, should be considered for active treatments as they still have a chance to recover by proper treatment.

AUTHORS’ AFFILIATIONS
1Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China; 2Department of Pathology, School of Basic Medical Sciences, Wuhan University, Wuhan, China; 3Wuchang District Center for Disease Control and Prevention, Wuhan, China; 4State Key Laboratory of Virology/Department of Medical Microbiology, School of Basic Medical Sciences, Wuhan University, Wuhan, China; 5Qingshan District Center for Disease Control and Prevention, Wuhan, China; 6Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan University, Hubei, China; 7Caidian District Center for Disease Control and Prevention, Wuhan, China; 8Xinzhou District Center for Disease Control and Prevention, Wuhan, China; 9Dermatology Hospital, Southern Medical University, and the University of North Carolina at Chapel Hill Project-China, Guangzhou, China

COMPETING INTERESTS
None declared.

AUTHORS’ CONTRIBUTIONS
WT and KL both have full access to all of the data. WG, YF, WT and KL conceived the research. FM, QZ, LL, PM and MG collected all the data. WG, YF, and KL analysed the data and drafted the manuscript. All authors have read and approved the final manuscript.

ACKNOWLEDGEMENTS
The authors thank all the participants for their contribution and thank all healthcare workers who involved in COVID-19 diagnosis and treatment of patients and thanked Ms. Gifty Marley for the proofreading of the manuscript.

FUNDING
This work was supported by the National Key Research and Development Program of China (2017YFE0103800), the National Nature Science Foundation of China (81903371), NIH (R34MH119963), the National Science and Technology Major Project (2018ZX10101-001-001-003) and Special Found on Prevention and Control of New Coronary Pneumonia in Guangdong Universities (2020KZDZX1047), Medical Science and Technology Innovation Platform Support Project of Zhongnan Hospital, Wuhan University (PTXM2020008), Science and Technology Innovation Cultivation Fund of Zhongnan Hospital, Wuhan University (exp2017043).

REFERENCES
1. Jiang H, Zhou Y, Tang W. Maintaining HIV care during the COVID-19 pandemic. Lancet HIV. 2020;7(5):e308–9.
2. Blanco JL, Ambrosioni J, García F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7(5):e314–6.
3. Zhu F, Cao Y, Xu S, Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. J Med Virol. 2020;92(6):529–30.
4. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269–70.
5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.
6. Xinhua. Chinese mainland reports 82,692 overall confirmed COVID-19 cases as Wuhan revises figures: official. Published 2020 Apr 17 [cited 2020 Apr 19]. Available from: http://www.xinhuanet.com/english/2020-04/17/c_138985339.htm
7. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
8. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020;221(11):1762–9.